Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by CHRISTOPHER J LOGOTHETIS and TIMOTHY THOMPSON.
CHRISTOPHER J LOGOTHETIS
Connection Strength
1.719
TIMOTHY THOMPSON
  1. ER stress in prostate cancer: A therapeutically exploitable vulnerability? Sci Transl Med. 2018 05 02; 10(439).
    View in: PubMed
    Score: 0.653
  2. Targeting the MYCN-PARP-DNA Damage Response Pathway in Neuroendocrine Prostate Cancer. Clin Cancer Res. 2018 02 01; 24(3):696-707.
    View in: PubMed
    Score: 0.158
  3. Androgen receptor inhibitor-induced "BRCAness" and PARP inhibition are synthetically lethal for castration-resistant prostate cancer. Sci Signal. 2017 May 23; 10(480).
    View in: PubMed
    Score: 0.153
  4. Caveolin-1 regulates hormone resistance through lipid synthesis, creating novel therapeutic opportunities for castration-resistant prostate cancer. Oncotarget. 2016 Jul 19; 7(29):46321-46334.
    View in: PubMed
    Score: 0.144
  5. Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers. Clin Cancer Res. 2016 Mar 15; 22(6):1520-30.
    View in: PubMed
    Score: 0.137
  6. The role of caveolin-1 in prostate cancer: clinical implications. Prostate Cancer Prostatic Dis. 2010 Mar; 13(1):6-11.
    View in: PubMed
    Score: 0.089
  7. Genome-wide DNA methylation profiling of leukocytes identifies CpG methylation signatures of aggressive prostate cancer. Am J Cancer Res. 2021; 11(3):968-978.
    View in: PubMed
    Score: 0.050
  8. Genetic variants in epithelial-mesenchymal transition genes as predictors of clinical outcomes in localized prostate cancer. Carcinogenesis. 2020 08 12; 41(8):1057-1064.
    View in: PubMed
    Score: 0.048
  9. Mitochondrial DNA copy number in peripheral blood leukocytes is associated with biochemical recurrence in prostate cancer patients in African Americans. Carcinogenesis. 2020 05 14; 41(3):267-273.
    View in: PubMed
    Score: 0.047
  10. Leukocyte telomere length is associated with aggressive prostate cancer in localized prostate cancer patients. EBioMedicine. 2020 Feb; 52:102616.
    View in: PubMed
    Score: 0.046
  11. Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial. Lancet Oncol. 2019 10; 20(10):1432-1443.
    View in: PubMed
    Score: 0.045
  12. Genetic associations of T cell cancer immune response with tumor aggressiveness in localized prostate cancer patients and disease reclassification in an active surveillance cohort. Oncoimmunology. 2019; 8(1):e1483303.
    View in: PubMed
    Score: 0.042
  13. Low serum testosterone is associated with tumor aggressiveness and poor prognosis in prostate cancer. Oncol Lett. 2017 Mar; 13(3):1949-1957.
    View in: PubMed
    Score: 0.037
  14. Genetic variants of the Wnt signaling pathway as predictors of aggressive disease and reclassification in men with early stage prostate cancer on active surveillance. Carcinogenesis. 2016 Oct; 37(10):965-971.
    View in: PubMed
    Score: 0.036
  15. Mitochondrial DNA copy number in peripheral blood leukocytes and the aggressiveness of localized prostate cancer. Oncotarget. 2015 Dec 08; 6(39):41988-96.
    View in: PubMed
    Score: 0.035
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.